GPMI
Global Precision Medical Inc., a fully reporting OTCBB company trading under the symbol GBPMF, is a Canadian based Medical Device Company that has entered into an exclusive worldwide Technology
License Agreement to commercialize the URO-Stent. The URO-Stent is used for the prevention of lumen restriction associated with benign prostate hyperplasia – BPH is a non-cancerous enlargement of the prostate, which constricts the urethra as it grows thereby restricting the flow of urine – a common cause of urinary voiding dysfunction in men.
The stent has been developed by a team of scientists, clinicians and medical specialists in Moscow in conjunction with IMET (world-renowned Institute of Metallurgy and Material Sciences in Moscow – Sputnik program, Russian Military and current Space Station). The unique shape-memory properties of the particular Nickel-Titanium (NiTi) formulation used in the device was developed and is produced by IMET where NiTi wire is braided into stents. The stent is released into the prostate by a catheter delivery system, and, as it reaches body temperature, the stent expands allowing the radial tension of the wire net to hold the blocked portion of the lumen in an open position. The URO-Stent has several advantages over competitive stent technologies: atraumatic design (no sharp ends), more radial rigidity, non-kinkable yet flexible while keeping the lumen diameter constant.
Top